Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Revenue (2022 - 2025)

Historic Revenue for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $1.4 million.

  • bioAffinity Technologies' Revenue fell 3847.54% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 2765.91%. This contributed to the annual value of $9.4 million for FY2024, which is 26967.52% up from last year.
  • According to the latest figures from Q3 2025, bioAffinity Technologies' Revenue is $1.4 million, which was down 3847.54% from $1.3 million recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Revenue high stood at $2.4 million for Q1 2024, and its period low was $921.0 during Q1 2023.
  • Moreover, its 4-year median value for Revenue was $1.4 million (2025), whereas its average is $1.2 million.
  • Its Revenue has fluctuated over the past 5 years, first surged by 26118023.89% in 2024, then crashed by 4705.31% in 2025.
  • Over the past 4 years, bioAffinity Technologies' Revenue (Quarter) stood at $2346.0 in 2022, then skyrocketed by 94245.95% to $2.2 million in 2023, then fell by 0.26% to $2.2 million in 2024, then plummeted by 34.5% to $1.4 million in 2025.
  • Its Revenue was $1.4 million in Q3 2025, compared to $1.3 million in Q2 2025 and $1.9 million in Q1 2025.